Our research unit, the MRGM (Rare Diseases: Genetics and Metabolism), was evaluated by HCERES in February 2021 (group B) under the supervision of the University of Bordeaux and INSERM.

The evaluation highlighted the good quality of the publications.

The strengths are:

– the constitution of well-characterized cohorts from a phenotypic point of view.

– the establishment of appropriate therapies.

– the numerous national and international collaborations.

– the existence of a zebrafish platform.

– its good coaptation with the hospital university services and which is essential for the competitiveness of our INSERM 1211 unit.

To access the summary of our assessment, follow the link: https://www.hceres.fr/en/rechercher-une-publication/mrgm-maladies-rares-genetique-et-metabolisme-0

The MRGM together with the Department of Biological and Medical Sciences of the University of Bordeaux, have invited José Antonio Enríquez (Centro Nacional de Investigaciones Cardiovasculares – Madrid | Spain) to give a Seminar on April 14th, 2020.

Event info:

Amphitheater of the BROCCA Institute – University of Bordeaux
April 14th, 2020 at 11:00am.

Link to Enríquez Laboratory website.

An additional regulator of mitochondrial bioenergetics discovered by Rossignol’s group: the protein EIF3F stimulates OXPHOS through AMPK. A ChipSeq/Proteomics analysis.

https://www.nature.com/articles/s41388-019-1009-x

Two investigators of the MRGM have been promoted!

We are proud of Caroline Rooryck-Thambo and Giovianni Bénard who have been promoted to Hospital-Practitioner/Professor of the University of Bordeaux (PU-PH) and CNRS Director of Research, respectively. This highlights the great scientific and clinical achievements of these two members of the MRGM.

A new model of Human mitochondrial disease at MRGM: The baker’s yeast Saccharomyces cerevisiae.

The baker’s yeast Saccharomyces cerevisiae can be used to model human diseases including rare diseases involving mitochondria. This model allows not only to find drugs (pharmacological treatment) and genes (gene therapy) but also to better understand the molecular mechanisms of theses diseases.

More info at: Hereditary Spastic Paraplegia Type 7